- Home
- MNOV vs GNLX Comparison
MNOV vs GNLX Comparison
Compare MNOV & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- GNLX
- Stock Information
- Founded
- MNOV 2000
- GNLX 2001
- Country
- MNOV United States
- GNLX United States
- Employees
- MNOV N/A
- GNLX N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- GNLX Health Care
- Exchange
- MNOV Nasdaq
- GNLX Nasdaq
- Market Cap
- MNOV 68.2M
- GNLX 109.4M
- IPO Year
- MNOV 2005
- GNLX 2023
- Fundamental
- Price
- MNOV $1.23
- GNLX $3.08
- Analyst Decision
- MNOV Strong Buy
- GNLX Strong Buy
- Analyst Count
- MNOV 2
- GNLX 4
- Target Price
- MNOV $7.00
- GNLX $17.75
- AVG Volume (30 Days)
- MNOV 20.6K
- GNLX 155.2K
- Earning Date
- MNOV 08-07-2025
- GNLX 08-13-2025
- Dividend Yield
- MNOV N/A
- GNLX N/A
- EPS Growth
- MNOV N/A
- GNLX N/A
- EPS
- MNOV N/A
- GNLX N/A
- Revenue
- MNOV N/A
- GNLX N/A
- Revenue This Year
- MNOV N/A
- GNLX N/A
- Revenue Next Year
- MNOV N/A
- GNLX N/A
- P/E Ratio
- MNOV N/A
- GNLX N/A
- Revenue Growth
- MNOV N/A
- GNLX N/A
- 52 Week Low
- MNOV $1.12
- GNLX $1.60
- 52 Week High
- MNOV $2.55
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- MNOV 40.69
- GNLX 52.03
- Support Level
- MNOV $1.32
- GNLX $2.80
- Resistance Level
- MNOV $1.38
- GNLX $3.61
- Average True Range (ATR)
- MNOV 0.04
- GNLX 0.23
- MACD
- MNOV 0.00
- GNLX 0.02
- Stochastic Oscillator
- MNOV 36.87
- GNLX 38.37
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.